Acurx Pharmaceuticals LLC
web2Acurx Pharmaceuticals is a clinical-stage biotechnology company developing antibiotics for diff...
About
Acurx Pharmaceuticals is a clinical-stage biotechnology company developing antibiotics for difficult bacterial infections, including infections caused by organisms resistant to existing treatments. Formerly organized as Acurx Pharmaceuticals LLC, the business converted into a Delaware corporation in 2021 and now operates as Acurx Pharmaceuticals Incorporated. Its lead investigational antibiotic, ibezapolstat, is being developed for infections caused by Clostridioides difficile, which can produce severe diarrhea and intestinal inflammation. The compound targets bacterial DNA polymerase IIIC, an enzyme involved in DNA replication. Other early research programs investigate compounds against Gram-positive pathogens, while ibezapolstat remains in clinical development without marketing approval.
Explore this sector
Exchange listings
Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.
Acurx Pharmaceuticals LLC profile.
Expert coverage
No published expert evaluations are available for this project yet.
Orbitrum Academy